Remifentanil has been approved in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Remifentanil studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
ULT101653 IV A centre randomized, open-label, cross-over study to compare the pharmaco-economic consequences of an Ultivaź (Remifentanil Hydrochloride) based regimen with conventional sedative based regimens in ICU subjects requiring short-term mechanical ventilation with analgesia and sedation.
USA30225 IV An economic evaluation of an analgesia-based sedation regimen with remifentanil supplemented with propofol compared to a conventional sedation regimen with midazolam/fentanyl in the ICU for patients after cardiac surgery
USA40036 IV A randomised, single-blinded study to evaluate the efficacy and safety of remifentanil versus sufentanil in patients undergoing coronary artery bypass graft surgery and/or valve surgery
USA30206 III A randomised, double-blind, parallel group, multi-centre study comparing the safety and efficacy of a remifentanil and propofol regimen versus a fentanyl and propofol regimen, including an investigation of the pharmacokinetics of remifentanil and remifentanil acid, in Intensive Care Unit patients requiring analgesia and sedation in association with short-term mechanical ventilation.
USA30207 III A randomised, double-blind, parallel group, multi-centre study comparing the safety and efficacy of a remifentanil and midazolam regimen versus a morphine and midazolam regimen in Intensive Care Unit patients requiring analgesia and sedation in association with short-term mechanical ventilation.
USA30212 III An open label, non-comparator, multi-centre study to assess the safety, efficacy and pharmacokinetics of remifentanil in Intensive Care Unit patients with varying degrees of renal dysfunction requiring analgesia and sedation in association with mechanical ventilation.
USA30217 III A Randomised, open, multicentre, parallel group study comparing the safety and efficacy of an Ultiva (remifentanil HCL) + propofol/midazolam regimen versus fentanyl + propofol/midazolam or morphine + propofol/midazolam regimens in mechanically ventilated intensive care unit subjects with brain injury requiring analgesia and sedation.
USA30226 III A randomised, open-label, multicentre, parallel group study comparing the safety and efficacy of an Ultiva (remifentanil hydrochloride) based analgesia/sedation regimen with a conventional sedative-based regimen in long-term ICU subjects requiring analgesia and sedation for up to 10 days.
USA30229 III A randomized, open-label, multicentre study comparing the safety and efficacy of a remifentanil + propofol sedoanalgesia regimen versus morphine + propofol regimen in Intensive Care Unit mechanically ventilated patients with medical pathology.